PARP1 Cancer Research Results

PARP1, Poly [ADP-ribose] polymerase 1: Click to Expand ⟱
Source:
Type:
PARP1 accounts for 90% of the PARP family of enzymes. PARP-1 (poly(ADP-ribose)-polymerase 1), mainly known for its protective role in DNA repair, also regulates inflammatory processes.
The close connection between PARP1 and the tumor suppressor protein p53 is also of great interest to those who study the complex role of PARP1 in cancer promotion or suppression.
PARP1 inhibition, which blocks the JNK-PARP1-JNK loop and ERK-mediated anti-apoptotic protein expression, will result in cancer apoptosis.

PARP1 Overexpression:
In several cancer types—including breast, ovarian, prostate, and lung cancers—elevated PARP1 expression and/or activity has been reported.
High PARP1 expression in certain cancers has been associated with aggressive tumor behavior and resistance to therapies (especially those that induce DNA damage).
Increased PARP1 activity may correlate with poorer overall survival in tumors that rely on DNA repair for survival.
Scientific Papers found: Click to Expand⟱
3541- ALA,    Insights on alpha lipoic and dihydrolipoic acids as promising scavengers of oxidative stress and possible chelators in mercury toxicology
- Review, Var, NA
*antiOx↑, *IronCh↑, *GSH↑, *BBB↑, Apoptosis↑, MMP↓, ROS↑, lipid-P↑, PARP1↑, Casp3↑, Casp9↑, *NRF2↑, *GSH↑, *ROS↓, RenoP↑, ChemoSen↑, *BG↓,
416- Api,    In Vitro and In Vivo Anti-tumoral Effects of the Flavonoid Apigenin in Malignant Mesothelioma
- vitro+vivo, NA, NA
Bax:Bcl2↑, P53↑, ROS↑, Casp9↑, Casp8↑, cl‑PARP1↑, p‑ERK⇅, p‑JNK↓, p‑p38↑, p‑Akt↓, cJun↓, NF-kB↓, EGFR↓, TumCCA↑,
5173- Ash,  2DG,    Withaferin A inhibits lysosomal activity to block autophagic flux and induces apoptosis via energetic impairment in breast cancer cells
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468 - in-vitro, BC, T47D
autoF↓, lysosome↓, TumAuto↑, p‑LDH↓, ATP↓, AMPK↑, eff↑, TumCG↓, CTSD↓, CTSB↓, CTSL↑, cl‑PARP1↑, LDHA↓, TCA↓,
4816- ASTX,    Potent carotenoid astaxanthin expands the anti-cancer activity of cisplatin in human prostate cancer cells
- in-vitro, Pca, NA
*antiOx↑, *Inflam↓, ChemoSen↑, E-cadherin↑, N-cadherin↓, VEGF↓, cMyc↓, PSA↓, cl‑Casp3↑, PARP1↑,
5634- BCA,    Molecular Mechanisms of Biochanin A in AML Cells: Apoptosis Induction and Pathway-Specific Regulation in U937 and THP-1
- in-vitro, AML, U937 - in-vitro, AML, THP1
Apoptosis↑, Casp7↑, PARP1↑, Bcl-2↓, Myc↓, CHOP↑, P21↑, p62↑, TumCCA↑, TXNIP↑, ROS↑, *antiOx↑, *Inflam↓, *neuroP↑, AntiCan↑, TumCP↓, angioG↓, TumMeta↓, VEGF↓, MMPs↓, tumCV↓, DNAdam↑, CHOP↑, cMyc↓, BioAv↓, Half-Life↓, BioAv↑,
2717- BetA,    Betulinic Acid Induces ROS-Dependent Apoptosis and S-Phase Arrest by Inhibiting the NF-κB Pathway in Human Multiple Myeloma
- in-vitro, Melanoma, U266 - in-vivo, Melanoma, NA - in-vitro, Melanoma, RPMI-8226
Apoptosis↑, TumCCA↑, MMP↓, ROS↑, eff↓, NF-kB↓, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, cl‑PARP1↑, MDA↑, SOD↓, SOD2↓, GCLM↓, GSTA1↓, FTH1↓, GSTs↓, TumVol↓,
444- CUR,  Cisplatin,    LncRNA KCNQ1OT1 is a key factor in the reversal effect of curcumin on cisplatin resistance in the colorectal cancer cells
- vitro+vivo, CRC, HCT8
TumVol↓, Apoptosis↑, Bcl-2↓, Cyt‑c↑, BAX↑, cl‑Casp3↑, cl‑PARP1↑, miR-497↑, KCNQ1OT1↓,
5151- GamB,    Gambogic acid affects ESCC progression through regulation of PI3K/AKT/mTOR signal pathway
- in-vitro, ESCC, KYSE-30 - in-vitro, ESCC, KYSE450
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, Bcl-2↓, BAX↑, cl‑PARP1↑, cl‑Casp3↑, cl‑Casp9↑, PI3K↓, p‑Akt↓, p‑mTOR↓, PTEN↑,
1015- NarG,    Naringin induces endoplasmic reticulum stress-mediated apoptosis, inhibits β-catenin pathway and arrests cell cycle in cervical cancer cells
- in-vitro, Cerv, SiHa - in-vitro, Cerv, HeLa - in-vitro, Cerv, C33A
ER Stress↑, p‑eIF2α↑, CHOP↑, PARP1↑, Casp3↑, β-catenin/ZEB1↓, GSK‐3β↓, p‑β-catenin/ZEB1↓, p‑GSK‐3β↓, TumCCA↑, P21↑, p27↑,
4941- PEITC,    PEITC: A resounding molecule averts metastasis in breast cancer cells in vitro by regulating PKCδ/Aurora A interplay
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
PKCδ↑, Apoptosis↓, selectivity↑, tumCV↓, p‑NRF2↑, cl‑PARP1↑, TumCMig↓, ROS↓, Hif1a↓,
3368- QC,    The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update
- Review, Var, NA
*Inflam↓, *antiOx↑, *AntiCan↑, Casp3↓, p‑Akt↓, p‑mTOR↓, p‑ERK↓, β-catenin/ZEB1↓, Hif1a↓, AntiAg↓, VEGFR2↓, EMT↓, EGFR↓, MMP2↓, MMP↓, TumMeta↓, MMPs↓, Akt↓, Snail↓, N-cadherin↓, Vim↓, E-cadherin↑, STAT3↓, TGF-β↓, ROS↓, P53↑, BAX↑, PKCδ↓, PI3K↓, COX2↓, cFLIP↓, cycD1/CCND1↓, cMyc↓, IL6↓, IL10↓, Cyt‑c↑, TumCCA↑, DNMTs↓, HDAC↓, ac‑H3↑, ac‑H4↑, Diablo↑, Casp3↑, Casp9↑, PARP1↑, eff↑, PTEN↑, VEGF↓, NO↓, iNOS↓, ChemoSen↑, eff↑, eff↑, eff↑, uPA↓, CXCR4↓, CXCL12↓, CLDN2↓, CDK6↓, MMP9↓, TSP-1↑, Ki-67↓, PCNA↓, ROS↑, ER Stress↑,
2329- RES,    Resveratrol induces apoptosis in human melanoma cell through negatively regulating Erk/PKM2/Bcl-2 axis
- in-vitro, Melanoma, A375
P53↑, Bcl-2↓, BAX↑, Cyt‑c↑, ERK↓, PKM2↓, Apoptosis↑, γH2AX↑, Casp3↑, cl‑PARP1↑,

Showing Research Papers: 1 to 12 of 12

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 12

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GCLM↓, 1,   GSTA1↓, 1,   GSTs↓, 1,   lipid-P↑, 1,   MDA↑, 1,   p‑NRF2↑, 1,   ROS↓, 2,   ROS↑, 5,   SOD↓, 1,   SOD2↓, 1,  

Metal & Cofactor Biology ⓘ

FTH1↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   MMP↓, 3,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   cMyc↓, 3,   p‑LDH↓, 1,   LDHA↓, 1,   PKM2↓, 1,   TCA↓, 1,  

Cell Death ⓘ

Akt↓, 1,   p‑Akt↓, 3,   Apoptosis↓, 1,   Apoptosis↑, 6,   BAX↑, 4,   Bax:Bcl2↑, 1,   Bcl-2↓, 4,   Casp3↓, 1,   Casp3↑, 5,   cl‑Casp3↑, 3,   Casp7↑, 1,   Casp8↑, 2,   Casp9↑, 4,   cl‑Casp9↑, 1,   cFLIP↓, 1,   Cyt‑c↑, 4,   Diablo↑, 1,   iNOS↓, 1,   p‑JNK↓, 1,   miR-497↑, 1,   Myc↓, 1,   p27↑, 1,   p‑p38↑, 1,  

Transcription & Epigenetics ⓘ

cJun↓, 1,   ac‑H3↑, 1,   ac‑H4↑, 1,   KCNQ1OT1↓, 1,   tumCV↓, 2,  

Protein Folding & ER Stress ⓘ

CHOP↑, 3,   p‑eIF2α↑, 1,   ER Stress↑, 2,  

Autophagy & Lysosomes ⓘ

autoF↓, 1,   lysosome↓, 1,   p62↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   DNMTs↓, 1,   P53↑, 3,   PARP1↑, 5,   cl‑PARP1↑, 7,   PCNA↓, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   P21↑, 2,   TumCCA↑, 5,  

Proliferation, Differentiation & Cell State ⓘ

CTSB↓, 1,   CTSD↓, 1,   CTSL↑, 1,   EMT↓, 1,   ERK↓, 1,   p‑ERK↓, 1,   p‑ERK⇅, 1,   GSK‐3β↓, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 1,   p‑mTOR↓, 2,   PI3K↓, 2,   PTEN↑, 2,   STAT3↓, 1,   TumCG↓, 1,  

Migration ⓘ

AntiAg↓, 1,   CLDN2↓, 1,   CXCL12↓, 1,   E-cadherin↑, 2,   Ki-67↓, 1,   MMP2↓, 1,   MMP9↓, 1,   MMPs↓, 2,   N-cadherin↓, 2,   PKCδ↓, 1,   PKCδ↑, 1,   Snail↓, 1,   TGF-β↓, 1,   TSP-1↑, 1,   TumCI↓, 1,   TumCMig↓, 2,   TumCP↓, 2,   TumMeta↓, 2,   TXNIP↑, 1,   uPA↓, 1,   Vim↓, 1,   β-catenin/ZEB1↓, 2,   p‑β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   EGFR↓, 2,   Hif1a↓, 2,   NO↓, 1,   VEGF↓, 3,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   CXCR4↓, 1,   IL10↓, 1,   IL6↓, 1,   NF-kB↓, 2,   PSA↓, 1,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 1,   ChemoSen↑, 3,   eff↓, 1,   eff↑, 5,   Half-Life↓, 1,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 2,   IL6↓, 1,   Ki-67↓, 1,   p‑LDH↓, 1,   Myc↓, 1,   PSA↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   RenoP↑, 1,   TumVol↓, 2,  
Total Targets: 131

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 4,   GSH↑, 2,   NRF2↑, 1,   ROS↓, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 3,  

Clinical Biomarkers ⓘ

BG↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   neuroP↑, 1,  
Total Targets: 10

Scientific Paper Hit Count for: PARP1, Poly [ADP-ribose] polymerase 1
1 Alpha-Lipoic-Acid
1 Apigenin (mainly Parsley)
1 Ashwagandha(Withaferin A)
1 2-DeoxyGlucose
1 Astaxanthin
1 Biochanin A
1 Betulinic acid
1 Curcumin
1 Cisplatin
1 Gambogic Acid
1 Naringin
1 Phenethyl isothiocyanate
1 Quercetin
1 Resveratrol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:400  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page